NanoViricides, Inc. Press Release

NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19
Sep 16, 2020 18:15 JST

NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.
More info..

Strong Effectiveness of NanoViricides Drug Candidates Observed in an Animal Model of Infection by an ACE2-using Human Coronavirus
May 20, 2020 18:15 JST

NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, announced today that strong effectiveness against infection by an ACE2-utilizing coronavirus in an animal model has been observed for the drug candidates it is developing against SARS-CoV-2 to treat COVID-19 spectrum of diseases.
More info..

Coronavirus Drug Development Update from NanoViricides, Inc. Mar 16, 2020 18:15 JST NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, is providing an update on its efforts towards drug development for the current novel coronavirus SARS-CoV-2 that causes COVID-19. More info..

NanoViricides has filed Quarterly Report for period ending December 31, 2019; Sufficient Cash, HerpeCide(TM) Drug Candidate IND Application Development in Progress
Feb 27, 2020 09:00 JST

NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its second quarter of financial year 2020 in a timely manner with the Securities and Exchange Commission.
More info..